Haleon plc (NYSE:HLN) Shares Bought by Royal Bank of Canada

Royal Bank of Canada raised its position in Haleon plc (NYSE:HLN - Free Report) by 62.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,733,615 shares of the company's stock after acquiring an additional 1,052,462 shares during the quarter. Royal Bank of Canada owned approximately 0.06% of Haleon worth $26,078,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in HLN. Wellington Management Group LLP lifted its stake in Haleon by 67.5% in the fourth quarter. Wellington Management Group LLP now owns 15,328,325 shares of the company's stock worth $146,232,000 after acquiring an additional 6,175,835 shares during the last quarter. Point72 Asset Management L.P. purchased a new stake in shares of Haleon during the 4th quarter worth approximately $45,110,000. Raymond James Financial Inc. purchased a new stake in shares of Haleon during the 4th quarter worth approximately $42,193,000. FMR LLC lifted its position in shares of Haleon by 3.7% during the 4th quarter. FMR LLC now owns 108,827,814 shares of the company's stock worth $1,038,217,000 after buying an additional 3,909,545 shares during the last quarter. Finally, Bank Julius Baer & Co. Ltd Zurich purchased a new stake in shares of Haleon during the 4th quarter worth approximately $39,628,000. Hedge funds and other institutional investors own 6.67% of the company's stock.

Haleon Stock Performance

Shares of Haleon stock traded up $0.10 during trading on Tuesday, reaching $11.24. The company's stock had a trading volume of 15,185,663 shares, compared to its average volume of 8,272,818. The company has a 50-day moving average price of $10.32 and a two-hundred day moving average price of $9.92. The firm has a market cap of $50.66 billion, a PE ratio of 33.06, a P/E/G ratio of 2.82 and a beta of 0.24. Haleon plc has a fifty-two week low of $8.25 and a fifty-two week high of $11.35. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44.

Haleon (NYSE:HLN - Get Free Report) last announced its earnings results on Thursday, February 27th. The company reported $0.05 EPS for the quarter. The business had revenue of $3.54 billion for the quarter, compared to analysts' expectations of $3.38 billion. Haleon had a net margin of 10.85% and a return on equity of 14.76%. On average, analysts forecast that Haleon plc will post 0.43 EPS for the current year.

Haleon Increases Dividend

The company also recently disclosed a -- dividend, which will be paid on Thursday, June 5th. Shareholders of record on Friday, April 25th will be paid a $0.1166 dividend. This is a boost from Haleon's previous -- dividend of $0.05. This represents a yield of 1.6%. The ex-dividend date is Friday, April 25th. Haleon's payout ratio is currently 58.97%.

Analysts Set New Price Targets

Several analysts have recently weighed in on the stock. Wall Street Zen downgraded shares of Haleon from a "buy" rating to a "hold" rating in a research report on Thursday, May 22nd. BNP Paribas Exane upgraded shares of Haleon from a "neutral" rating to an "outperform" rating and set a $13.40 price objective for the company in a research report on Tuesday. Hsbc Global Res downgraded shares of Haleon from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, March 5th. Morgan Stanley upgraded shares of Haleon from an "equal weight" rating to an "overweight" rating and set a $11.25 price objective for the company in a research report on Friday, May 9th. Finally, HSBC restated a "hold" rating on shares of Haleon in a research report on Wednesday, March 5th. Six investment analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Haleon has a consensus rating of "Moderate Buy" and a consensus price target of $12.33.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.